Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Colorcon
Moodys
McKinsey
Johnson and Johnson

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,399,071

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,399,071
Title:Methods of treatment of pancreatic cancer
Abstract: The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:13/701,002
Patent Claims:1. A method of treating pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, wherein the individual has progressed on a gemcitabine-based therapy, and wherein the gemcitabine-based therapy has stopped for at least 6 months when initiating administration of the effective amount of the nanoparticle composition.

2. The method of claim 1, wherein the progression is within less than about 12 months.

3. A method of treating resistant pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin, wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, wherein the individual was subjected to a prior gemcitabine-based therapy, and wherein the prior gemcitabine-based therapy has stopped for at least 6 months when initiating administration of the effective amount of the nanoparticle composition.

4. A method of treating recurrent pancreatic cancer in an individual in need thereof, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with an albumin wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm, wherein the individual was subjected to a prior gemcitabine-based therapy, and wherein the prior gemcitabine-based therapy has stopped for at least 6 months when initiating administration of the effective amount of the nanoparticle composition.

5. The method of claim 1, wherein the gemcitabine-based therapy further comprises erlotinib.

6. The method of claim 1, wherein the gemcitabine-based therapy is monotherapy.

7. The method of claim 1, further comprising administering to the individual an effective amount of another agent.

8. The method of claim 7, wherein the other agent is selected from the group consisting of 5-fluororuracil, erlotinib, gefitnib, marimastat, irinotecan, tipifarnib, pemetrexed, exatecan, capecitabine, raltitrexed, cetuximab, bevacizumab, bortezomib, rapamycin, and vandetanib.

9. The method of claim 1, wherein the pancreatic cancer is exocrine pancreatic cancer or endocrine pancreatic cancer.

10. The method of claim 9, wherein the exocrine pancreatic cancer is pancreatic ductal carcinoma.

11. The method of claim 1, wherein the pancreatic cancer is locally advanced pancreatic cancer, unresectable pancreatic cancer, or metastatic pancreatic ductal carcinoma.

12. The method of claim 1, wherein the individual is human.

13. The method of claim 1, wherein levels of serum CA19-9 (carbohydrate antigen 19-9) in the individual are decreased by at least about 50% in comparison to the levels of serum CA19-9 prior to the treatment.

14. The method of claim 3, wherein the gemcitabine-based therapy is monotherapy.

15. The method of claim 3, further comprising administering to the individual an effective amount of another agent.

16. The method of claim 3, wherein the individual is human.

17. The method of claim 4, wherein the gemcitabine-based therapy is monotherapy.

18. The method of claim 4, further comprising administering to the individual an effective amount of another agent.

19. The method of claim 4, wherein the individual is human.

Summary for Patent:   Start Trial

PCT Information
PCT FiledMay 20, 2011PCT Application Number:PCT/US2011/037462
PCT Publication Date:December 08, 2011PCT Publication Number:WO2011/153010

Details for Patent 9,399,071

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA) 2030-06-04 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA) 2030-06-04 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA) 2030-06-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Harvard Business School
Medtronic
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.